Introduction
============

Neuroblastoma (NB) is the most common type of pediatric extracranial cancer, accounting for approximately 15% of all cancer deaths in children [@B1], [@B2]. It could arise in any part of sympathetic nervous system, especially in adrenal medulla and abdomen [@B3]. The clinical presentation is highly variable, ranging from local invasion and distant metastasis [@B4]. Although advanced immunotherapy and multiple cytotoxic therapies are applied, the survival rate of high-risk NB remains below 50% [@B4], [@B5]. However, the complex pathogenesis of NB is still not well understood. Therefore, it is of great significance to explore the molecular mechanism of NB in order to accelerate the development of novel drugs and therapy methods.

Although only about 1% of NB patients are heredofamilial, accumulating evidences indicate the complicated genomic abnormalities play significant roles in NB heterogeneity [@B6], [@B7]. To recognize tumor genetic variations, genome-wide association studies (GWASs) are considered as a powerful and hypothesis-free method [@B8]. Based on GWAS results, multiple genetic variations associated with NB risk have been identified, such as *ALK*, *FLJ22536*, *FLJ44180*, *BARD1*, *LMO1*, *HACE1* and *LIN28B*[@B9]-[@B15]. The earliest GWAS on NB was performed by Maris and colleagues in 2008, including 1032 cases and 2043 controls in European American, which validated that chromosome 6p22 locus was associated with clinically aggressive NB[@B10]. In high-risk NB, they further found six SNPs were associated with NB susceptibility in *the BRCA1 associated RING domain 1 (BARD1)* gene [@B11]. Moreover, these *BARD1* SNPs has been confirmed in both Italians [@B16] and African-Americans [@B17]. In Chinese population, three *BARD1* SNPs have been studied in NB, but only stratified analysis demonstrated that rs3768716 and rs6435862 were risk factors for aggressive NB [@B18]. As a result, further systematic research and functional assessment of SNPs in *BARD1* gene need to be performed. In addition, identifying SNPs in Chinese population is informative and it can explore potential ethnic differences and strengthen the role of *BARD1* as locus of NB susceptibility.

Herein, we performed a systematic screening of the SNPs in *BARD1* and investigated the function of SNPs located in functional regions such as 5\'-UTR and exon. We selected eleven candidate SNPs in *BARD1* gene and carried out a case-control study in a total of 339 NB patients and 778 cancer-free controls. Association analysis indicated that seven SNPs contributed to NB risk. Functional evaluation of SNPs in 5\'-UTR and exon region revealed that rs17489363 G \> A might influence *BARD1* promoter activity in four haplotypes. The major aim of our study was to discover the association between*BARD1* SNPs and NB susceptibility, and further explore the precise molecular mechanism of the functional SNPs.

Methods and Materials
=====================

Ethics statement
----------------

This study was approved by the Ethics Committee of the Beijing Children\'s Hospital, Capital Medical University (Beijing, China). The written informed consents have been obtained from participants and/or their legal guardians involved in this study prior to inclusion in the study.

Subjects and clinical information
---------------------------------

Volunteers were enrolled from January 2004 to December 2016 at Beijing Children\'s Hospital, which is the National Center for Children\'s Health (NCCH). A total of 339 NB patients and 778 cancer-free controls were recruited. Even the subjects were from all over the country, more than half of them were from Northern of China. To avoid minority differences of genetic background, all the volunteers in our research were Han Chinese children. According to the International Neuroblastoma Pathology Classification (INPC) [@B19], we stratified cases into three pathological groups, namely Neuroblastoma (NB), Ganglioneuroma (GN) and Ganglioneuroblastoma (GNB). In addition, the tumor stage was classified based on the International Neuroblastoma Staging System (INSS) by two professional pathologists. All controls were health children, admitted by physical examination center of Beijing Children\'s Hospital. All recruited volunteers were collected EDTA-anticoagulated blood samples for this research, and stored at -80^o^C.

SNPs screening
--------------

We used computer-facilitated strategy to select candidate SNPs in *BARD1* gene. The following steps were operated (Figure [1](#F1){ref-type="fig"}). Firstly, candidate SNPs were filtered by using the Haploview (<http://www.broad.mit.edu/mpg/haploview/>) with selection criteria of minor allele frequency (MAF) \> 0.05 and r^2^ values \> 0.8 from Han Chinese in Beijing (CHB) in the 1000 Genomes database (<https://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/>). The candidate SNPs screening region extended to a 2 kb (1kb upstream and 1kb downstream the gene). Secondly, to identify functional SNPs in *BARD1*, we excluded synonymous mutations and unconfirmed intron SNPs.

Sample preparation and genotyping
---------------------------------

DNA Blood Mini Kit (Qiagen, Hilden, Germany) was used to extract Genomic DNA from 300μL peripheral blood of all samples, and then the DNAs were stored at -20^o^C until use. By using the SequenomMassArray platform, SNP genotyping was performed following the manufacturer\'s protocol (Sequenom, San Diego, USA) [@B13], [@B20].

Cell culture
------------

Human embryonic kidney cell line (293T) and human neuroblastoma cell line (SH-SY5Y) were obtained from Cell Resource Center, Chinese Academy of Medical Sciences (CAMS, Beijing, China). The cells were cultured in DMEM supplemented with 10% fetal bovine serum, in a humidified, 5% CO~2~ incubator at 37°C.

Plasmid construction
--------------------

Three SNPs (rs34732883 T \> C, rs17489363 G \> A and rs1129804 C \> G) located in 5\'-UTR of *BARD1*. For these SNPs, a GV238 reporter (Genechem, Shanghai, China) plasmid encompassing 5\'-UTR and truncated promoter region of *BARD1* was constructed, designated as pT-G-C according to sequence analysis. Subsequently, this pT-G-C was used as a template, 5\'-UTR site-specific mutagenesis in rs34732883 T \> C, rs17489363 G \> A and rs1129804 C \> G were performed to generate other constructs containing all of the possible haplotypes, namely pC-G-C, pT-G-G, pC-G-G, pT-A-C, pC-A-C, pT-A-G and pC-A-G (Figure [2](#F2){ref-type="fig"}A).

The exon SNP rs1048108 located near zinc finger ring region, which played a key role in the interaction of BARD1 and Breast cancer 1 (BRCA1). To explore the function of rs1048108, *BARD1* ORF expression plasmid (pCMV3-Myc-*BARD1*) was obtained from Sino Biological lnc (Beijing, China). This plasmid with rs1048108 C allele was named as BARD1-Myc-CC. Then, site-specific mutagenesis was performed to creating single nucleotide mutation in rs1048108 C \> T, named as BARD1-Myc-TT accordingly. All constructs were sequenced to confirm their authenticity.

Daul-luciferase reporter assay
------------------------------

Total of 1×10^5^ cells were plated in 24-well plates (Corning, NY, USA) and grew to 80-90% confluence for transient transfection with Lipofectamine 2000 Reagent (Life Technologies, Inc., Rockville, USA). Cells were then transfected with 50 ng/well of reporter plasmid. Identically, Renilla luciferase reporter plasmid (10 ng/well) was co-transfected for standardization of the transfection efficiencies. Luciferase activity was measured by the Dual-Luciferase Reporter Assay system (Promega, Madison, USA) on a microplate reader (CLARIOstar, BMG labtech, Germany) according to the manufacturer\'s protocol. Results were normalized by Renilla activity, and labeled as relative luciferase activity. Three independent transfection experiments were performed, and each was done in triplicate.

Co-immunoprecipitation (Co-IP) and Western blotting
---------------------------------------------------

To study the interaction between BARD1 and BRCA1, we obtained the human BRCA1 ORF expression plasmid (pcDNA3-HA-BRCA1) from Sino Biological lnc (Beijing, China). Co-IP was performed as follows. Briefly, 293T cells were co-transfected with plasmid containing*BRCA1* gene (pcDNA3-HA-BRCA1) and plasmid containing different genotype *BARD1* gene (BARD1-Myc-CC or BARD1-Myc-TT) for 48 h. Proteins were then extracted with RIPA cell lysis buffer (Dingguo, Beijing). Total cell protein extracts were incubated with anti-HA antibody (Abcam, UK) overnight at 4^o^C followed by immunoprecipitation with protein A agarose beads (Roche, Switzerland). The beads were washed, collected and resolved in prechilled RIPA lysis buffer for six times. Finally, the protein-agarose complexes were boiled for SDS-PAGE. Immunoblots were carried out according to the standard operating procedure. The relative densities of the desired protein bands were quantified by Image Lab software (Bio-Rad, USA).

Statistical Analysis
--------------------

A two-sided χ2 test was performed to describe the distribution of the age and gender between cases and controls, as well as the deviation of genotypes. All samples were detected for Hardy-Weinberg equilibrium by Goodness-of-fit χ2 test. In order to get an exact result, we analyzed the association between the polymorphisms and NB susceptibility by using the multivariate logistic regression analysis to assess Odds ratios (ORs) and 95% Confidence intervals (95%CIs) with age and gander as covariates. The *P* value below 0.05 from either model was considered statistically significant. Bonferroni test was carried out to adjust for multiple comparisons in the single SNP analysis (*P* \< 0.05/n, n=11). All statistical analyses described above were computed using SAS software (version 9.1; SAS Institute, Cary, NC). Haploview 4.2[@B21] was used to measure the LD and the haplotype.

Results
=======

Clinical characteristics
------------------------

To analyze the association between NB risk and *BARD1* SNPs, 339 cases and 778 controls were recruited in Beijing Children\'s Hospital from January 2004 to December 2016 (Table [1](#T1){ref-type="table"}). Two groups were matched with gender and age (*P* \> 0.05). Pathological types classified by INPC were categorized into NB (240, 70.80%), GN (33, 9.73%), and GNB (59, 17.40%). According to INSS, the case group was divided into stage I (45, 13.27%), II (59, 17.40%), III (99, 29.20%), IV (109, 32.15%) and IVs (24, 7.08%). Besides, among these 339 cases, 152 (44.84%) of the primary tumors located in adrenal gland and 171 (51.33%) developed from non-adrenal regions including abdominal/retroperitoneal region (137, 40.41%), pelvic cavity (20, 5.90%), and other sites (14, 4.13%). The remaining 13 (3.83 %) cases were not classified into a specific region.

Identification of SNPs
----------------------

Based on the screening strategy (Figure [1](#F1){ref-type="fig"}), eleven candidate SNPs were selected for further study, including three SNPs in 5\'-UTR (rs34732883, rs17489363 and rs1129804), three SNPs in exon (rs2229571, rs3738888 and rs1048108), and five SNPs in intron (rs3768716, rs6435862, rs3768707, rs17487792 and rs7587476) (Table [2](#T2){ref-type="table"}).

Since linkage disequilibrium (LD) represented correlating genotypes between SNPs at different loci [@B22], the pair-wise LD between these eleven SNPs were measured by Haploview software. The disequilibrium coefficient *D\'* and *r^2^* were represented of the proportion or the maximum possible disequilibrium. The results showed that three SNPs in 5\'-UTR were in strong LD in our study population, with a *D\'* of 0.99 (*r^2^* = 0.97) for rs34732883 and rs1129804 (*P* \< 0.001), a *D\'* of 1.00 (*r^2^* = 0.98) for rs34732883 and rs17489363 (*P* \< 0.001), and a *D\'* of 1.00 (*r^2^* = 0.99) for rs17489363 and rs1129804 (*P* \< 0.001). In exon, rs2229571 and rs1048108 also showed strong LD (*D\'* = 0.88,*r^2^* = 0.7, *P* \< 0.001) (Supplement Figure [1](#F1){ref-type="fig"}).

Effect of *BARD1* SNPs on NB Risk
---------------------------------

To explore the effect of eleven candidate SNPs on NB risk, the genotype differences were compared between 339 NB cases and 778 controls. By multivariate logistic regression analysis, we found that seven SNPs were significantly associated with NB risk (Table [3](#T3){ref-type="table"}), with one in 5\'-UTR (rs17489363 G \> A), two in exon (rs2229571 G \> C and rs3738888 C \> T), and four in intron (rs3768716 A \> G, rs6435862 T \> G, rs3768707 C \> T and rs17487792 C \> T). However, the relationship between different haplotypes and NB risk were not detected (data not shown).

Stratification analysis of identified SNPs
------------------------------------------

For further estimating the association between seven identified SNPs and NB, we stratified the cases according to tumor categories, tumor stages and primary tumor sites. As shown in Supplementary Table [1](#SM0){ref-type="supplementary-material"}, six SNPs were associated with malignant type GNB/NB rather than mature type GN. With regards to tumor stages, NB in stage III was related to rs3768707 C \> T and rs3768716 A \> G, while NB in stage IV was related to rs2229571 C \> G, rs6435862 T \> G, rs17487792 C \> T and rs3768716 A \> G. Based on tumor location, all the SNPs showed significant association with primary NB located in adrenal. These results indicated that the seven SNPs in *BARD1* might contribute to NB aggressiveness.

Effect of identified SNPs on *BARD1* transcriptional activity
-------------------------------------------------------------

We have confirmed that rs17489363 G \> A in 5\'-UTR was a risk SNP and it had strong LD with rs34732883 T \> C and rs1129804 C \> G, therefore the potential haplotypes should be considered in*BARD1* transcriptional activity. Thus, the Dual-luciferase reporter assay was performed. Compared to reporter gene expressions driven by the rs17489363 G allele *BARD1* promoters, all of rs17489363 A allele-containing counterparts showed 1.2- to 4- fold lower transcriptional activity both in 293T and SH-SY5Y cells (*P* \< 0.05, Figure [2](#F2){ref-type="fig"}B & [2](#F2){ref-type="fig"}C). The results suggested that rs17489363 G \> A may play a major function on *BARD1* promoter activity in these haplotypes.

The function of SNPs in *BARD1* exon
------------------------------------

To explore the function of SNPs in BARD1 exon, we first overviewed the protein structure of BARD1. According to UniProt database (<http://www.uniprot.org/>), BARD1 had a BRCA1-interaction region (M26-E119), three ANK repeats (R427-P546) and two BRCT1 domains (M560-I653 and L667 -S777) (Figure [3](#F3){ref-type="fig"}A). The main function of BARD1 was to interact with BRCA1 via the zinc finger ring region and rs1048108 C \> T (P24S) located near the domain. Moreover, rs1048108 had prominent LD with rs2229571 (D\'=0.9, r^2^=0.7), suggesting potential correlating between these two SNPs (Supplementary Figure [1](#SM0){ref-type="supplementary-material"}). Even rs2229571 (R378S) and rs3738888 (R658C) were risk SNPs, their sites were away from the functional domain. Thus, we chose rs1048108 C \> T as the representative SNP for functional study of BARD1 protein. Therefore, we performed Co-IP to assess if rs1048108 could directly affect BARD1-BRCA1 interaction. As shown in Figure [3](#F3){ref-type="fig"}B, BARD1 protein containing rs1048108 T allele did not show any difference in BRCA1 binding capacity compared to the protein containing the rs1048108 C allele. This Co-IP result suggested that rs1048108 C \> T (P24S) has no detectable influence on the BARD1/BRCA1 heterodimer.

Discussion
==========

Neuroblastoma is the most common pediatric extracranial solid tumor and causes increasing concern on pediatrics due to its malignancy. Several studies have revealed that genetic factors could raise NB risk [@B9]-[@B15]. *BARD1*, as an important tumor suppressor gene [@B23], has been verified significantly associated with NB susceptibility in different ethnicities [@B11], [@B16], [@B17], [@B24]. However, the significance of *BARD1* SNPs in Chinese population is far from clear. Thus, the present study was performed to screen significant SNPs in the whole length of *BARD1* in Chinese population. Herein, seven risk SNPs for NB were identified and four rs17489363 A allele-containing haplotypes (composed with rs34732883 T \> C and rs1129804 C \> G) were demonstrated to affect transcriptional activity of*BARD1* gene.

The seven identified SNPs included one in 5\'-UTR (rs17489363 G \> A), two in exon (rs2229571 G \> C and rs3738888 C \> T), and four in intron (rs3768716 A \> G, rs6435862 T \> G, rs3768707 C \> T and rs17487792 C \> T). Previous studies have demonstrated that rs17489363, rs3768716 and rs6435862 contributed to NB risk [@B11], [@B16], [@B17], [@B24]. The study in South Chinese population reported that subjects carrying risk alleles of rs3768716 or rs6435862 had a significant trend on NB developing in clinical stage III/IV patients [@B18]. However, the significant association was failed to be found in total subjects. In our study, significant association appeared in both total subjects and stratification analysis, the larger sample size might contribute to the difference (339 cases and 778 controls in our study vs 201 cases and 501 controls in the study on South Chinese population). Consistent with our results, Capasso et al. also elicited that rs3768716 and rs6435862 polymorphisms were the most significant variants that associated with NB risk in European ancestry [@B11]. What\'s important is that a novel SNP rs3738888 was identified associated with NB risk in our study, which was not reported before in European, American African, Italian or Chinese [@B11], [@B16], [@B17], [@B24].

Functional studies of identified SNPs were further analyzed according to their locations. Among the seven identified SNPs, SNP rs17489363 G \> A was located in 5\' -UTR of *BARD1*. By using *in silico* approach, previous study found that rs17489363 might alter the transcriptional binding site of *BARD1* [@B25], and the latest study clarified this perspective *in vitro* [@B24]. In the present study, we further confirmed the influence of rs17489363 on*BARD1* transcriptional activity. Due to rs17489363 was in strong LD with rs34732883 and rs1129804 and LD represented correlating genotypes between these SNPs, the functions of different genotypes should be concerned. Compared to rs17489363 G allele-containing counterparts, the four rs17489363 A allele-containing haplotypes (composed with rs34732883 T \> C and rs1129804 C \> G) were shown to reduce the transcriptional activity of*BARD1* gene. As a result, haplotypes containing rs17489363 A might play a key role in*BARD1* promoter activity.

The BARD1\'s function is also related to protein structure. BARD1 interacts with BRCA1 via the zinc finger ring region [@B26]-[@B28] and to enhance the stability of BRCA1 [@B29]. According to UniProt database, rs1048108 C \> T (P24S) located near the domain. Even rs2229571 (R378S) and rs3738888 (R658C) were found associated with NB susceptibility, their sites were away from the interaction region. Moreover, rs1048108 C \> T is in prominent LD with rs2229571 G \> C, which suggested potential correlating between these two SNPs. However, our result suggested that rs1048108 C \> T (P24S) has no detectable influence on the BARD1/BRCA1 heterodimer.

For SNPs located in intron region, four SNPs (rs3768716 A \> G, rs6435862 T \> G, rs3768707 C \> T and rs17487792 C \> T) were significantly associated with NB susceptibility. The same results were also obtained in European ancestry [@B11]. Moreover, previous study has reported that NB cells with the rs6435862 G risk allele could significantly increase the expression of one of *BARD1* splice variant, *BARD1*β [@B30]. Since the splice variant *BARD1*β was an oncogenic driver of high-risk NB tumorigenesis, the G risk allele may participant in the development of NB risk through increasing *BARD1*β expression [@B30].

Several limitations of this study should be mentioned. Firstly, all of the participants were recruited from Beijing Children\'s Hospital, including 339 cases and 778 controls. However, most of our patients were lived in the North of China. Although we have adjusted age and gender as the concomitant variable, we couldn\'t ignore the existent bias of participants\' born places. Secondly, as there were eight haplotypes composed with rs34732883, rs17489363 and 1129804, the sample size of per group was small. Thus, the statistical power maybe limited. Therefore, we observed strong effects on *BARD1* transcriptional activity *in vitro*, but found weak relationship between haplotypes and NB risk in SNP analysis. Thirdly, we did not complete 3-years\' follow-up for monitoring far-reaching influence. In our future researches, both biological and clinical approaches would be considered and the sample size would be enlarged.

Conclusion
==========

In conclusion, our study revealed the relationship between identified SNPs in *BARD1* and NB susceptibility by systematically whole genetic scanning in Chinese population. Seven identified SNPs in*BARD1* significantly contributed to NB risk. In addition, four rs17489363 A allele-containing haplotypes in 5\'-UTR could reduce the promoter activity of *BARD1 in vitro.* These findings have provided novel clues to investigate the genetic mechanism of NB.
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![The schematic for the strategy of SNP selection.](jcav10p2153g001){#F1}

![Dual-luciferase reporter assay with constructs containing *BARD1* promoter. (A) Schematic of reporter gene constructs having the *BARD1* promoter, with different haplotypes containing three SNPs in *BARD1* 5\'-UTR (rs34732883, rs17489363 and 1129804). 293T cells (B) and SH-SY5Y (C) were co-transfected with 50 ng of the reporter plasmid and 10 ng of Renilla luciferase reporter plasmid for standardization of the transfection efficiencies. The luciferase activity was expressed as Mean ± S.E. of the ratio of firefly expression of *BARD1* promoters. (\*) indicate *P* \< 0.05 with respect to the general (without stimulation). Abbreviation: NC, negative control.](jcav10p2153g002){#F2}

![(A) The BARD1 structure. The amino acid mutation caused by rs1048108, rs2229571 and rs3738888 in BARD1 were indicated. Rs1048108 (P24S) located near zinc finger ring region, which played a key role in the interaction of BARD1 and BRCA1. (B) Effect of the rs1048108 C or T allele on BARD1-BRCA1 interaction. Co-IP result showed no difference in BARD1-BRCA1 interaction between wild type and mutant type of rs1048108 C \> T (P24S).](jcav10p2153g003){#F3}

###### 

Distribution of Subject Characteristics

                            Case (N=339)           Controls (N=778)   *P*^\*^           
  ------------------------- -------------- ------- ------------------ --------- ------- ------
  **Sex**                                                                               
  **Male**                  194            57.23                      453       58.23   0.76
  **Female**                144            42.48                      325       41.77   
  **Unknown**               1              0.29                       0         0.00    
  **Age**                                                                               
  **≤12months**             64             18.87                      144       18.51   0.91
  **\>12months**            275            81.13                      633       81.36   
  **Unknown**               0              0.00                       1         0.13    
  **Tumor stage^a^**                                                                    
  **I**                     45             13.27                                        
  **II**                    59             17.40                                        
  **III**                   99             29.20                                        
  **IV**                    109            32.15                                        
  **IVs**                   24             7.08                                         
  **Unknown**               3              0.88                                         
  **Categories^b^**                                                                     
  **GN**                    33             9.73                                         
  **GNB**                   59             17.4                                         
  **NB**                    240            70.80                                        
  **Unknown**               7              2.06                                         
  **Primary tumor sites**                                                               
  **Adrenal**               152            44.84                                        
  **Abdominal**             137            40.41                                        
  **Pelvic**                20             5.90                                         
  **Others**                14             4.13                                         
  **Unknown**               13             3.83                                         

^\*^Two-sided χ^2^ test. ^a^ According to INSS. ^b^ According to INPC.

###### 

Basic Information of Potential *BARD1* SNPs

  \#   Identity     Position(GRCh37)   Position   Base change   MAF^a^
  ---- ------------ ------------------ ---------- ------------- --------
  1    rs17489363   Ch2:214809617      5\'-UTR    G\>A          0.18
  2    rs34732883   Ch2:214809647      5\'-UTR    T\>C          0.18
  3    rs1129804    Ch2:214809599      5\'-UTR    C\>G          0.18
  4    rs2229571    Ch2:214780740      exon       G\>C          0.34
  5    rs3738888    Ch2:214730440      exon       C\>T          0.04
  6    rs1048108    Ch2:214809500      exon       C\>T          0.37
  7    rs3768716    Ch2:214771070      intron     A\>G          0.15
  8    rs6435862    Ch2:214807822      intron     T\>G          0.09
  9    rs3768707    Ch2:214780411      intron     C\>T          0.23
  10   rs17487792   Ch2:214778776      intron     C\>T          0.14
  11   rs7587476    Ch2:214789163      intron     C\>T          0.23

Abbreviation: MAF, minor allele frequency.

^a^ Data from CHB population in 1000 Genomes project

###### 

Associations between *BARD1* SNPs and NB Risk

                   Cases(N=339)          Controls(N=778)   *P*   Adjusted OR^a^ (95%CI)              
  ---------------- -------------- ------ ----------------- ----- ------------------------ ---------- ------------------
  **rs17489363**                                                                                     
  **GG**           206            61.0                     529   68.9                                1.00
  **GA**           114            33.7                     217   28.3                     0.03       1.26 (0.95-1.68)
  **AA**           18             5.3                      22    2.9                      0.035      2.04 (1.06-3.92)
  **rs34732883**                                                                                     
  **TT**           197            61.2                     504   68.3                                1.00
  **CT**           109            33.9                     212   28.7                     0.082      1.24(0.93-1.66)
  **CC**           16             5.0                      22    3.0                      0.088      1.81(0.93-3.56)
  **rs1129804**                                                                                      
  **CC**           135            39.8                     302   39.8                                1.00
  **CG**           163            48.1                     254   46.6                     0.84       1.08 (0.81-1.43)
  **GG**           42             12.1                     103   13.6                     0.78       0.98(0.64-1.51)
  **rs2229571**                                                                                      
  **CC**           67             20.0                     232   30.1                                1.00
  **CG**           164            49.0                     370   48                       \<0.0001   1.74 (1.24-2.44)
  **GG**           104            31.0                     169   21.9                     \<0.0001   1.84 (1.37-2.49)
  **rs3738888**                                                                                      
  **CC**           323            95.3                     749   97.7                                1.00
  **CT**           16             4.7                      18    2.4                      0.041      2.17 (1.04-4.50)
  **TT**           \-             \-     \-                \-    \-                       \-         \-
  **rs1048108**                                                                                      
  **CC**           147            43.6                     307   39.8                                1.00
  **CT**           154            45.7                     369   47.9                     0.60       0.93(0.70-1.23)
  **TT**           36             10.7                     95    12.3                     0.39       0.83(0.55-1.27)
  **rs3768716**                                                                                      
  **AA**           211            63.0                     555   71.8                                1.00
  **AG**           111            33.1                     200   25.9                     0.014      1.49 (1.12-1.99)
  **GG**           13             3.9                      18    2.3                      0.26       1.53 (0.73-3.21)
  **rs6435862**                                                                                      
  **TT**           232            68.8                     594   76.9                                1.00
  **GT**           96             28.5                     168   21.8                     0.029      1.40(1.04-1.90)
  **GG**           9              2.7                      10    1.3                      0.13       2.05(0.81-5.18)
  **rs3768707**                                                                                      
  **CC**           183            54.6                     499   64.4                                1.00
  **CT**           132            39.4                     242   31.4                     0.013      1.45(1.10-1.92)
  **TT**           20             6.0                      31    4.0                      0.18       1.73(0.95-3.15)
  **rs17487792**                                                                                     
  **CC**           209            64.7                     545   72.4                                1.00
  **CT**           104            32.2                     192   25.5                     0.04       1.45(1.08-1.95)
  **TT**           10             3.1                      16    2.1                      0.52       1.31(0.58-2.95)
  **rs7587476**                                                                                      
  **CC**           179            54.9                     343   59.5                                1.00
  **CT**           126            38.6                     206   35.8                     0.59       1.04(0.77-1.41)
  **TT**           21             6.4                      27    4.7                      0.32       1.37(0.74-2.56)

^a^Data were calculated by logistic regression analysis with adjustment for sex and age as covariate
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